Ongoing clinical studies

SynAct-CS003

The SynAct-CS003 study is an explorative, double-blind, multi-center, randomized, placebo-controlled study of safety, tolerability, pharmacokinetics, and efficacy of treatment with AP1189 in patients with idiophathic membranous nephropathy (iMN).

The study is designed to test safety tolerability and efficacy of AP1189 vs. placebo given as an add on to ACE inhibitor or angiotensin II receptor blocker treatment.

The study is planned to enroll 23 patients (minimum of 18 patients) who are treated with 100 mg AP1189 or placebo in a 2:1 randomization.

Status: Recruiting.

For further information on the study setup see clinicaltrials.gov

SynAct-CS007 (EXPAND)

The SynAct-CS007 study is a study to assess the safety & efficacy of treatment with AP1189 in Rheumatoid Arthritis patients naïve to DMARD treatment (EXPAND).

The study is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of 12 weeks expanded daily treatment with 100 mg AP1189 in RA patients who are to start up-titration with methotrexate (MTX).

Status: Recruiting.

For further information on the study setup see clinicaltrials.gov